Molina Healthcare Earnings Call Transcripts
Fiscal Year 2026
-
Premium revenue is projected to grow from $42B to $64B by 2029, driven by balanced organic growth, new contracts, and M&A, with a focus on margin restoration and operational discipline. Margin recovery targets a 2.5% pre-tax margin and $25 EPS, supported by embedded earnings and efficiency gains.
-
Q1 2026 delivered solid results with $2.35 adjusted EPS and $10.2B premium revenue. Full-year guidance is reaffirmed at ~$42B revenue and at least $5 EPS, despite higher Medicaid attrition, offset by Marketplace gains. Medical cost trends are stabilizing and capital position remains strong.
-
Management reaffirmed 2026 guidance and highlighted $11 per share in embedded earnings from future wins. Medicaid trends reflect higher acuity and underfunding, but margin recovery is expected by 2027 as rates catch up. Strategic focus shifts to duals, leveraging integrated care and regulatory changes.
Fiscal Year 2025
-
Q4 and full-year 2025 results missed expectations due to trend pressures and retroactive Medicaid items, but future growth is supported by major contract wins and a robust pipeline. 2026 guidance is cautious, with EPS at least $5, and embedded earnings power exceeding $11 per share.
-
Q3 2025 results missed expectations due to elevated medical costs, especially in Marketplace, leading to a reduced full-year EPS outlook of ~$14. Medicaid remains strong despite pressure, while Marketplace and Medicare face ongoing challenges. 2026 guidance anticipates revenue growth from new contracts and a more conservative Marketplace strategy.
-
Q2 results showed $5.48 adjusted EPS and $10.9B premium revenue, but persistent medical cost pressures led to a guidance cut for 2025 EPS to no less than $19. Marketplace and Medicaid segments face elevated MCRs, with growth targets and M&A pipeline intact.
-
Q1 delivered strong EPS and revenue, with robust cost management and reaffirmed 2025 guidance. Medicaid and Medicare segments performed in line with expectations, while Marketplace MCR was impacted by non-recurring items. Growth initiatives and M&A pipeline support long-term targets.
Fiscal Year 2024
-
Q4 and full-year 2024 results showed strong revenue growth but higher-than-expected medical costs, especially in Medicaid and Medicare, led to results below guidance. Growth initiatives, acquisitions, and new contracts support a bullish 2025 outlook with 9% revenue growth and at least $24.50 EPS guidance.
-
Revenue is projected to reach $52–$55 billion by 2027, with 11%–13% annual growth driven by organic expansion, strategic initiatives, and M&A. EPS is expected to grow 13%–15% annually, supported by disciplined cost management, robust capital allocation, and a strong M&A pipeline.
-
Q3 results met expectations with $6.01 EPS and $9.7B premium revenue, but higher medical costs in Medicaid and Medicare raised MCRs. Full-year guidance is reaffirmed, with strong Marketplace performance and new contract wins supporting long-term growth.
-
Q2 2024 results met expectations with $5.86 EPS and $9.4B premium revenue. Full-year guidance is reaffirmed, with strong Medicare and Marketplace performance offsetting Medicaid cost pressures. Growth is supported by acquisitions, contract wins, and robust capital position.